At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19).

Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1

• If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1
• If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1

For current NICE guidance, please refer to 'COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders' www.nice.org.uk/guidance/ng167.

At this time, Lilly has not studied the use of ixekizumab in patients at risk of contracting COVID-19.

The decision on treatment remains at the discretion of prescribing physician.

COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.1

Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.2

Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2

For further information please refer to the Taltz SmPC.

Lilly = Eli Lilly and Company

WHO = World Health Organization